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Abstract
Background: Monocyte-derived macrophages critically perpetuate inflammatory responses after liver injury as a
prerequisite for organ fibrosis. Experimental murine models identified an essential role for the CCR2-dependent infiltration
of classical Gr1/Ly6C
+ monocytes in hepatic fibrosis. Moreover, the monocyte-related chemokine receptors CCR1 and CCR5
were recently recognized as important fibrosis modulators in mice. In humans, monocytes consist of classical CD14
+CD16
2
and non-classical CD14
+CD16
+ cells. We aimed at investigating the relevance of monocyte subpopulations for human liver
fibrosis, and hypothesized that ‘non-classical’ monocytes critically exert inflammatory as well as profibrogenic functions in
patients during liver disease progression.
Methodology/Principal Findings: We analyzed circulating monocyte subsets from freshly drawn blood samples of 226
patients with chronic liver disease (CLD) and 184 healthy controls by FACS analysis. Circulating monocytes were significantly
expanded in CLD-patients compared to controls with a marked increase of the non-classical CD14
+CD16
+ subset that
showed an activated phenotype in patients and correlated with proinflammatory cytokines and clinical progression.
Correspondingly, CD14
+CD16
+ macrophages massively accumulated in fibrotic/cirrhotic livers, as evidenced by
immunofluorescence and FACS. Ligands of monocyte-related chemokine receptors CCR2, CCR1 and CCR5 were expressed
at higher levels in fibrotic and cirrhotic livers, while CCL3 and CCL4 were also systemically elevated in CLD-patients. Isolated
monocyte/macrophage subpopulations were functionally characterized regarding cytokine/chemokine expression and
interactions with primary human hepatic stellate cells (HSC) in vitro. CD14
+CD16
+ monocytes released abundant
proinflammatory cytokines. Furthermore, CD14
+CD16
+, but not CD14
+CD16
2 monocytes could directly activate collagen-
producing HSC.
Conclusions/Significance: Our data demonstrate the expansion of CD14
+CD16
+ monocytes in the circulation and liver of
CLD-patients upon disease progression and suggest their functional contribution to the perpetuation of intrahepatic
inflammation and profibrogenic HSC activation in liver cirrhosis. The modulation of monocyte-subset recruitment into the
liver via chemokines/chemokine receptors and their subsequent differentiation may represent promising approaches for
therapeutic interventions in human liver fibrosis.
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Introduction
Sustained inflammation is a common characteristic of chronic
liver injury in mice and men and induces the development of liver
fibrosis [1,2]. Monocytes are circulating blood leukocytes that play
important roles in the pathogenesis of inflammatory disorders,
because they serve as precursors for tissue macrophages and
dendritic cells [3]. Over recent years, several studies have
emphasized the crucial role of infiltrating monocytes for the
progression of liver fibrosis in experimental mouse models
[4,5,6,7,8,9]. It has become clear that the macrophage compart-
ment of the liver, traditionally called ‘Kupffer cells’, is constantly
replenished to a significant extent by blood monocytes [4,10] and
is greatly augmented by a vast number of infiltrating monocytes
upon acute or chronic liver injury [6,11]. During fibrosis
progression in mice, monocyte-derived macrophages release
cytokines perpetuating chronic inflammation as well as directly
activate hepatic stellate cells (HSC), resulting in their proliferation
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11049and transdifferentiation into collagen-producing myofibroblasts
[5,6,9]. Independent studies highlighted the importance of the
chemokine receptor CCR2 and its cognate ligand monocyte-
chemoattractant protein 1 (MCP-1/CCL2) for monocyte recruit-
ment during experimental hepatic fibrosis [5,6,7,8]. Moreover,
CCR1 and CCR5, receptors for the chemokines CCL3/MIP1a,
CCL4/MIP1b and CCL5/RANTES, promote liver fibrosis in
mice [11].
Human and mouse blood each contain two main monocyte
subsets, which can be distinguished by high or low Gr1 (Ly6C)
expression (‘Gr1
hi or Gr1
lo monocytes’) in mice [12]. We
demonstrated previously that only Gr1
hi monocytes are massively
recruited into the murine liver upon toxic injury dependent on
CCR2-mediated bone marrow egress, constituting an up to 10-
fold increase in CD11b
+F4/80
+ intrahepatic macrophages. During
chronic liver damage, Gr1
hi monocyte-derived cells differentiate
into iNOS-producing macrophages exerting proinflammatory and
profibrogenic actions [6]. At present it is unclear how these
findings from mouse models precisely relate to liver diseases in
humans. It is well established that the number of macrophages
increases during chronic liver injury and fibrogenesis [4], but
detailed phenotypic characterizations of human intrahepatic
monocyte-derived cells are lacking at present. Mouse Gr1
hi
monocytes are believed to resemble the human CD14
+CD16
2,
and Gr1
lo the human CD14
+CD16
+ subset [12]. This assumption
is based on similar expression patterns of activation markers,
adhesion molecules and chemokine receptors. Namely, CCR1 and
CCR2 are more highly expressed on CD14
+CD16
2 human and
Gr1
hi mouse monocytes, whereas CCR5 is elevated on
CD14
+CD16
+ human and Gr1
lo mouse monocytes [12,13,14]. It
is believed that CD14
+CD16
+ monocytes originate from
CD14
+CD16
2 cells and represent the more mature/differentiated
monocyte subset [12].
However, some discrepancies between murine and human
monocyte subpopulations have not been convincingly resolved at
present. For instance, Gr1
hi monocytes constitute about 50% of
murine monocytes, while CD14
+CD16
2 cells represent about 90–
95% of human monocytes [12]. In mice, Gr1
hi monocytes are
often named ‘inflammatory monocytes’ due to their preferential
recruitment to sites of inflammation and their proinflammatory
differentiation potential, whereas in humans the CD14
+CD16
+
subset has long been considered to constitute ‘inflammatory
monocytes’, because it is found upregulated in many inflammatory
disorders and has the potential to release high amounts of
proinflammatory cytokines upon stimulation in vitro [3,15]. In
patients with liver cirrhosis, both increased peripheral
CD14
+CD16
2 and CD14
+CD16
+ monocytes have been reported
from small clinical studies [16,17].
As the interference with monocyte subset infiltration, differen-
tiation and activation may represent interesting novel targets for
future therapeutic approaches in liver fibrosis [4], we aimed at
defining the functional contributions of monocyte subpopulations
to liver fibrogenesis in humans. Our study, comprising 226
patients with chronic liver diseases (CLD) at various stages of
fibrosis/cirrhosis from different disease etiologies and 184 controls,
demonstrates that circulating monocytes increase during disease
progression, specifically the CD14
+CD16
+ subset. Correspond-
ingly, CD14
+CD16
+ monocytes/macrophages massively accumu-
late in the fibrotic/cirrhotic liver. Monocyte-related chemokine
pathways are differentially activated in the liver and circulation of
patients with liver disease. Functionally, CD14
+CD16
+ monocytes
likely perpetuate intrahepatic inflammation via secretion of
proinflammatory cytokines, but also directly activate profibrogenic
HSC.
Results
Blood monocytes increase in patients with chronic liver
disease, are associated with disease progression and shift
towards the ‘non-classical’ CD16
+ monocyte subset
Recent reports from experimental liver injury in mouse models
demonstrated an important functional role of the inflammatory
Ly6C
hi (Gr1
hi) monocyte subset for the progression of liver fibrosis,
because the chemokine-driven accumulation of these monocyte-
derived intrahepatic macrophages crucially perpetuates hepatic
inflammation and can promote activation of hepatic stellate cells
(HSC) as the main collagen-producing cells in the liver [6,18]. In
order to translate these findings from animal models into human
pathogenesis, we subjected peripheral blood of 226 patients with
chronic liver diseases (CLD) and 184 healthy controls to
immediate FACS analysis. CLD patients had significantly higher
circulating monocytes than controls, both as relative contribution
to WBC (p=0.002) as well as in absolute cell counts (p=0.002,
Fig. 1A–C, Table 1). Increasing monocyte numbers were
associated with disease progression, specifically with the progres-
sion from non-cirrhotic to cirrhotic disease (Fig. 1A–C, Table 1).
Patients with end-stage cirrhosis (Child C) showed higher blood
monocytes than early stages of liver cirrhosis (p=0.001, Fig. 1C).
Moreover, there were inverse correlations between monocyte
counts and parameters indicating the hepatic biosynthetic
capacity, such as serum albumin (r=20.305, p,0.001), pro-
thrombin time (r=20.310, p,0.001) or pseudocholinesterase
activity (r=20.324, p,0.001), and positive correlations to
serological fibrosis markers, e.g. pro-collagen-III-peptide
(r=0.432, p,0.001) and hyaluronic acid (r=0.241, p=0.001,
Fig. 1D, Table 2). Higher blood monocytes were also found in
patients with clinical complications of CLD, such as icterus,
encephalopathy, ascites or esophageal varices (data not shown).
However, in patients with established liver cirrhosis, monocyte
counts were not indicative of clinical complications (not shown).
In humans, the ‘classical’ CD14
+CD16
2 monocytes share many
characteristics with murine Gr1
hi (Ly6C
hi) monocytes, whereas
‘non-classical’ CD14
+CD16
+ cells are considered counterparts of
murine Gr1
lo (Ly6C
lo) monocytes [13]. The CD14
+CD16
+ subset
has long been thought to constitute ‘inflammatory monocytes’ in
humans [12]. Strikingly, we observed a strong shift towards the
CD14
+CD16
+ monocyte subset in CLD patients, especially in
patients with established cirrhosis (Fig. 2A–B). The increase in
absolute numbers of both subsets, however, did not reach
statistical significance (Fig. S1). The relative abundance of
CD14
+CD16
+ monocytes was correlated with inflammatory
cytokines and parameters indicative of disease progression, while
CD14
+CD16
2 monocytes showed inverse correlations to these
markers (Table 2), indicating a contribution of CD14
+CD16
+
monocytes to the chronic inflammatory state of patients with CLD
and cirrhosis. Of note, we could not observe any differences in
monocyte counts or monocyte subsets between the different
underlying etiologies of CLD (data not shown), suggesting that the
quantitative and qualitative changes in the monocyte compart-
ment represent a rather uniform response during CLD progression
and fibrogenesis. However, patients with liver cirrhosis and
hepatocellular carcinoma (HCC) even displayed significantly
higher CD14
+CD16
+ monocytes than cirrhotic patients without
HCC (p=0.008, Fig. 2C).
A striking feature of the two major monocyte subpopulations is
their differential expression of the MHC-II molecule HLA-DR
[13], because CD14
+CD16
+ express HLA-DR much stronger
than the CD14
+CD16
2 cells (Fig. 2D). In CLD patients, HLA-DR
expression is significantly upregulated on CD14
+CD16
+ mono-
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markedly enhanced activation and maturation status. This results
in a significant increase in the ratio of HLA-DR expression
between both subsets in CLD patients and especially in those with
liver cirrhosis (p,0.001, Fig. 2E). Collectively, these data
demonstrate a substantial shift of circulating monocytes towards
the ‘non-classical’ monocyte subset that is associated with
inflammation, fibrosis and disease progression in CLD patients.
Intrahepatic CD16
+ macrophages predominantly
increase during liver fibrosis progression
It is well established that the number of macrophages increases
during chronic liver injury and fibrogenesis [4], but the phenotype
of intrahepatic monocyte-derived cells remains poorly defined.
Thus, we tested whether CD14
+CD16
2 and CD14
+CD16
+
monocyte/macrophage subpopulations are also present within
the liver. In fact, conventional histology already identified
mononuclear infiltrates in the portal regions of cirrhotic versus
normal liver (Fig. 3A), and immunohistochemical co-staining for
CD14 and CD16 was established to classify the intrahepatic
monocytes/macrophages (Fig. 3B). We observed a significant
increase of CD14
+CD16
+ cells in cirrhosis (p=0.02 compared to
F2–F3 fibrosis, p=0.001 compared to F0–F1), which account for
approximately 50% of the total intrahepatic monocytes/macro-
phages in cirrhotic, but only for about 10% in non-cirrhotic livers,
and mostly explain the total increase in hepatic macrophages in
cirrhosis (Fig. 3C). A similar trend was noticed when early stages of
fibrosis (scored F0 and F1 by a blinded pathologist) were compared
to progressive (F2–F3) and cirrhotic (F4) disease (Fig. 3D).
We next aimed to characterize these intrahepatic macrophage
subpopulations further and to establish the relationship between
intrahepatic and peripheral blood monocyte/macrophage subsets.
Unlike in peripheral blood (Fig. 2A), FACS analysis from freshly
obtained liver biopsies (n.30) revealed the existence of three
CD14
+ intrahepatic monocyte/macrophage populations (Fig. 4A)
that could be defined as CD14 high-expressing cells
(CD14
hiCD16
2), CD14 low-expressing cells and CD14/CD16
double-positive macrophages (CD14
+CD16
+). Characteristically,
CD14
hiCD16
2 hepatic cells expressed low HLA-DR and low DC-
SIGN (CD209), similar to peripheral CD14
+CD16
2 monocytes.
In contrast, the intrahepatic CD14
+CD16
+ cells expressed high
HLA-DR and some DC-SIGN (CD209), similar to peripheral
CD14
+CD16
+ monocytes (Fig. 4A). In addition, we found CD14
lo
cells which are negative for CD16, HLA-DR and DC-SIGN,
hence likely representing sessile hepatic macrophages (classical
Kupffer cells).
In order to further substantiate these observations, intrahepatic
macrophage subsets were directly compared to peripheral blood
Figure 1. Blood monocytes increase in patients with chronic liver disease and are associated with disease progression. (A) Monocytes
are defined by CD14 staining of PBMC (representative FACS plots shown). (B+C) Relative proportion of monocytes (CD14
+) (B) and absolute monocyte
numbers (C). (D) Association of circulating monocytes with laboratory parameters in CLD patients. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0011049.g001
Table 1. Characteristics of the patient cohort.
Healthy controls All patients Stages of liver cirrhosis
No cirrh. Child A Child B Child C
n 184 226 85 48 46 47
Sex (male/female) n 109/75 142/84 53/32 26/22 26/20 37/10
Age yrs 43 (16–68) 53 (17–82) 43 (17–73) 63 (30–82) 60 (28–77) 53 (21–81)
Liver disease etiology n n.a.
Viral hepatitis 89 49 19 15 6
Biliary/autoimmune 27 15 7 3 2
Alcohol 65 5 14 17 29
Other origin 45 16 8 11 10
Clinical complications n n.a.
Esophageal varices 85 0 21 29 35
Ascites 80 1 7 31 41
HCC 23 0 9 8 6
WBC x10
3/ml 5.9 (1.7–11.6) 6.1 (1.4–28.8) 5.8 (2.2–14.3) 6.3 (2.0–22.3) 5.3 (1.8–16.3) 6.85 (1.4–28.8)
Total monocytes x10
3/ml 0.55 (0.23–1.42) 0.68 (0.01–2.72) 0.60 (0.14–1.59) 0.69 (0.01–2.62) 0.61 (0.19–2.72) 0.86 (0.01–1.67)
CD14
+CD16
2 monocytes % 92.4 (78.2–97.9) 90.0 (72.1–98.7) 90.7 (78.2–98.7) 89.5 (72.1–97.6) 90.6 (77.2–97.1) 88.4 (77.1–98.7)
CD14
+CD16
2 monocytes x10
3/ml 0.50 (0.2–1.31) 0.61 (0.01–2.55) 0.54 (0.12–1.57) 0.59 (0.01–2.55) 0.57 (0.17–2.54) 0.74 (0.01–1.47)
CD14
+CD16
+ monocytes % 7.5 (2.1–21.9) 9.9 (1.1–27.4) 9.3 (1.1–21.7) 10.7 (2.5–27.4) 9.4 (2.9–23.0) 11.2 (1.3–22.9)
CD14
+CD16
+ monocytes x10
3/ml 0.04 (0.01–0.14) 0.06 (,0.01–0.5) 0.05 (0.01–0.17) 0.05 (,0.01–0.28) 0.06 (0.02–0.5) 0.09 (,0.01–0.38)
Serum MCP-1 pg/ml [CCL2] 88.3 (,1.3–237.0) 102.8 (,1.3–24794) 115.8 (16.8–365.2) 116.7 (17.2–24794) 90.3 (,1.3–904.8) 56.0 (,1.3–1484.5)
Serum MIP1a pg/ml [CCL3] ,1.3 (,1.3–2.8) 3.0 (,1.3–183.3) 2.2 (,1.3–60) 3.9 (,1.3–60) 4.5 (1.8–66.3) 3.4 (,1.3–183.3)
Serum MIP1(pg/ml [CCL4] 30.6 (,1.3–62.5) 47.2 (,1.3–443.9) 47.0 (,1.3–139.5) 53.7 (20.3–249.5) 46.7 (8.8–443.9) 41.6 (9.3–443.5)
For quantitative variables, the median is given with the range in parenthesis. n.a., not applicable; HCC, hepatocellular carcinoma; WBC, white blood cell count. For
chemokine serum concentrations, alternative names are given in square brackets.
doi:10.1371/journal.pone.0011049.t001
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principal similarities between intrahepatic CD14
+CD16
+ and
circulating CD14
+CD16
+ cells, intrahepatic CD16
+ macrophages
showed up-regulated HLA-DR, DC-SIGN and (moderately)
CD56 expression in comparison to their blood counterparts
(Fig. 4B), thereby indicating intrahepatic maturation of this
macrophage population. The CD14
hiCD16
2 cells, on the other
hand, express similar levels of HLA-DR as circulating
CD14
+CD16
2 monocytes, but differ by displaying higher levels
of the differentiation markers DC-SIGN and CD56 (Fig. 4B).
Interestingly, HLA-DR expression appeared down-regulated on
CD14
+CD16
+ intrahepatic macrophages in patients with ad-
vanced compared to early or absent fibrosis, while DC-SIGN was
up-regulated, further indicating an activated (pro-inflammatory)
state of this macrophage subpopulation in advanced fibrosis
(Fig. 4B).
Activation of monocyte-related chemokine pathways in
chronic liver disease
Our data demonstrate the distinct accumulation of CD16
+
monocytes in the liver during fibrosis progression, prompting us to
study possible chemokine pathways that are activated in CLD and
could mediate monocyte subset infiltration. In experimental
murine models, the chemokine receptors CCR2, CCR1 or
CCR5 that are differentially expressed on monocyte subsets have
been implicated in hepatic fibrosis progression [6,8,11]. In
humans, CCR2 is primarily expressed on CD14
+CD16
2 mono-
cytes, whereas CD14
+CD16
+ monocytes express higher levels of
CCR5 on their surface; CCR1 is expressed on both subsets, with
moderately higher levels on CD14
+CD16
2 monocytes [13,19,20].
Gene expression analysis from whole liver tissue at different stages
of fibrosis progression demonstrated a clear up-regulation of
intrahepatic ccr2 (F0-1 compared to F4 fibrosis, p=0.021), ccr5
(F0-1 compared to F4 fibrosis, p,0.0001) and ccr1 (F0-1 compared
to F4 fibrosis, p=0.0008) in fibrosis (Fig. 5A), which matches well
with the observed accumulation of monocytes in the fibrotic/
cirrhotic liver (Fig. 3). As not only monocytes/macrophages, but
also other immune cell subsets or non-parenchymal liver cells may
express these chemokine receptors [2], we performed FACS
analyses from fresh liver samples after biopsy and surgical
resection. CCR2 expression was primarily found on hepatic
monocytes/macrophages (defined as CD14
+ cells) and (at lower
Table 2. Correlation analysis.
total monocytes CD14
+CD16
2 monocytes CD14
+CD16
+ monocytes
R p r p r p
Clinical scores
Child-Pugh (points) 0.188 0.038 - n.s. - n.s.
MELD 0.190 0.031 - n.s. - n.s.
Liver function
Bilirubin total 0.242 0.000 20.202 0.004 0.174 0.013
Bilirubin conjugated 0.235 0.001 20.218 0.002 - n.s.
Albumin 20.305 ,0.001 20.179 0.011 - n.s.
PCHE 20.324 ,0.001 0.176 0.013 20.174 0.014
Prothrombin time (%) 20.310 ,0.001 - n.s. 20.223 0.001
INR 0.264 ,0.001 - n.s. 0.167 0.016
Factor V 20.172 0.023 - n.s. - n.s.
Fibrosis markers
Procollagen-III-peptide 0.432 ,0.001 20.315 ,0.001 0.307 ,0.001
Hyaluronic acid 0.241 0.001 - n.s. - n.s.
Inflammatory cytokines & chemokines
IL6 0.261 ,0.001 - n.s. - n.s.
TNFa 0.389 ,0.001 20.252 0.001 0.243 0.002
MCP-1 (CCL2) - n.s. - n.s. 0.261 0.002
MIP1b (CCL4) - n.s. - n.s. 0.150 0.043
MIG (CXCL9) - n.s. 20.265 0.002 - n.s.
IP-10 (CXCL10) 0.212 0.018 20.244 0.006 0.169 0.002
Hematology
Total WBC 0.282 ,0.001 - n.s. - n.s.
Lymphocyte count 20.635 ,0.001 - n.s. - n.s.
Platelets - n.s. - n.s. 20.186 0.007
Hemoglobin - n.s. 0.161 0.020 - n.s.
Correlation analysis (Spearman rank correlation test) between total monocytes, the relative abundance of CD14
+CD16
2 or CD14
+CD16
+ monocytes and clinical scores,
serum markers of liver function, inflammatory cytokine and chemokine serum concentrations and other blood counts are given in the table. Only significant results are
shown. MELD, model of end stage liver disease; PCHE, pseudocholinesterase; INR, international normalized ratio; IL, interleukin; WBC, white blood cell count; n.s.,n o t
significant.
doi:10.1371/journal.pone.0011049.t002
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CCR1 was expressed at high levels by almost all CD14
+ cells, but
also by subsets of T-, NK- and NKT-cells (Fig. 5B). CCR5
expression was primarily found on T-cells and subsets of NK- and
NKT-cells, but hepatic monocytes/macrophages also express
CCR5 at variable levels (Fig. 5B).
In line, hepatic mRNA expression of the chemokines ccl2 (F0-1
compared to F4 fibrosis, p=0.0088) and ccl5 (F0-1 compared to
F4 fibrosis, p,0.0001), but not of ccl3, was strongly up-regulated in
fibrosis (Fig. 5C). Moreover, the serum concentrations of the
CCR1/CCR5 ligands MIP1a (CCL3) and MIP1b (CCL4), but
not of the CCR2 ligand MCP-1 (CCL2), were significantly
increased in CLD patients (Fig. 5D), suggesting additional systemic
actions of these chemokines.
Given the expression of CCR2, CCR1 and CCR5 by hepatic
monocytes/macrophages, the local upregulation of ccl2 and ccl5 in
the whole liver and the systemic elevation of CCL3 (healthy
controls compared to CLD patients, p=0.0387) and CCL4
(healthy controls compared to CLD patients, p=0.0064) in the
circulation, we speculated that peripheral blood monocytes in
patients might regulate their chemokine receptor expression,
rendering them more prone to accumulate in the diseased liver.
Figure 3. Intrahepatic CD16
+ macrophages predominantly increase during liver fibrosis progression. (A) Representative examples of
biopsies from normal liver (upper panel) and cirrhotic liver (lower panel) show mononuclear inflammatory infiltrates in fibrotic periportal regions (left:
H&E staining, right: Ladewig staining, in which collagen stains blue). (B) Immunofluoresecent co-staining for CD14 (red) and CD16 (green) identifies
CD14
+CD16
2 and CD14
+CD16
+ macrophages in human liver tissue (blue: nuclei counterstained with DAPI). Bold arrow, CD14
+CD16
2 macrophage;
thin arrow, CD14
+CD16
+ macrophage. (C+D) Semiquantative analysis of CD14
+CD16
2, CD14
+CD16
+ and total CD14
+ intrahepatic cells. *p,0.05,
**p,0.001.
doi:10.1371/journal.pone.0011049.g003
Figure 2. Relative increase of CD14
+CD16
+ blood monocytes and more activated phenotype in patients with liver cirrhosis. (A)
Representative FACS plots displaying an increase of CD14
+CD16
+ monocytes (black gate: CD14
+CD16
2, grey gate: CD14
+CD16
+) among PBMC in
patients with cirrhosis compared to healthy controls and non-cirrhotic patients (left). The histograms show the relative distribution of CD16
expression on CD14
+ cells (right; grey: isotype control). (B) Statistical analysis of monocyte subsets. HC, healthy controls (n=181); CLD, patients
(n=226); NC, non-cirrhotic (n=85); CIR, cirrhotic (n=141). (C) Patients with liver cirrhosis and hepatocellular carcinoma (HCC) have significantly
(p=0.008) higher CD16
+ monocytes than cirrhotics without HCC. (D) Representative FACS staining for HLA-DR on monocyte subsets. (E) Ratio of HLA-
DR expression on CD16
+ vs. CD16
2 monocytes. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0011049.g002
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11049Figure 4. Intrahepatic macrophages consist of different subpopulations mirroring blood monocyte subsets. (A) FACS analysis of
intrahepatic monocytes/macrophages, based on .30 fresh liver biopsies. Representative plots are displayed. Among the CD45
+ intrahepatic
leukocytes, three different populations of intrahepatic CD14
+ macrophages can be distinguished based on CD14 and CD16 expression that also differ
characteristically in HLA-DR and DC-SIGN expression. (B) Expression levels of monocyte/macrophage activation and differentiation markers were
compared in the same patients between blood CD14
+CD16
2 monocytes (dotted line) and liver CD14
hiCD16
2 macrophages (dark grey) as well as
Monocytes Human Liver Fibrosis
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11049We therefore isolated circulating monocytes by CD14-microbeads
via MACS methodology from patients (n=113) and healthy
controls (n=32) at purities greater than 95% (not shown).
Monocytic ccr1 (p=0.031 for healthy controls compared to CLD
patients), but not ccr2 or ccr5, expression was increased on
peripheral monocytes in patients (Fig. 6A), possibly in response to
elevated serum levels of CCL3 and CCL4. With respect to
monocyte subsets, CCR2 was predominantly expressed on
CD14
+CD16
2 monocytes (Fig. 6B). On a protein level, CCR2
surface expression was modestly down-regulated on
CD14
+CD16
+ monocytes (dashed line) and liver CD14
+CD16
+ macrophages (light grey); representative analyses from patients with a F0 fibrosis (no
fibrosis, upper panel) and a F3 fibrosis (advanced fibrosis, lower panel) are shown. Isotype control, black line. Blood was drawn at the time of liver
biopsy, and blood/liver samples were run with the same FACS settings at the same time.
doi:10.1371/journal.pone.0011049.g004
Figure 5. Activation of monocyte-related chemokine pathways and of monocytic chemokine receptors in chronic liver disease. (A)
Intrahepatic gene expression levels of chemokine receptors. (B) Expression of CCR2, CCR1 and CCR5 was assessed by FACS on monocytes/
macrophages (CD14
+, green), T- (CD3
+CD56
2, light orange), NK- (CD3
2CD56
+, dark orange) and NKT-cells (CD3
+CD56
+, red) from freshly isolated liver
tissue. Representative histograms are shown, isotype control in grey. (C) Intrahepatic gene expression levels of chemokines. (D) Serum concentrations
of monocyte-related chemokines in patients with chronic liver diseases and healthy controls. Abbreviations are: HC, healthy control; CLD, chronic liver
disease; NC, no cirrhosis; CIR, cirrhosis. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0011049.g005
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+CD16
2 monocytes of patients as compared to healthy
controls, but not on CD14
+CD16
+ cells (Fig. 6B). Within the liver,
CD14
hiCD16
2 macrophages expressed CCR2 at similar (high)
levels as circulating CD14
+CD16
2 monocytes; liver CD14
+CD16
+
macrophages, in contrast, displayed lower levels than
CD14
hiCD16
2 macrophages, but higher CCR2 expression than
blood CD14
+CD16
+ monocytes, suggesting that the
CD14
+CD16
+ subset up-regulated CCR2 intrahepatically (de-
tailed data not shown). These results collectively revealed that
monocyte-related chemokines targeting CCR2 and CCR1/CCR5
are up-regulated in the intra- and extrahepatic compartment of
CLD patients.
Functionality of monocytes in liver cirrhosis and
differential cytokine and chemokine secretion by
monocyte subsets
Although we consistently found more circulating monocytes in
CLD patients and a close association with disease progression
(Fig. 1, Table 2), it remained unclear if these monocytes were fully
functionally active. It had been speculated before that monocyte
activation might be impaired in liver cirrhosis, contributing to a
so-called ‘‘immune-paralysis’’ in those patients [21,22]. We
therefore cultured isolated circulating monocytes from patients
with advanced liver cirrhosis (Child B/C, n=16) and matched
healthy controls (n=20) in media supplemented with autologous
serum and assessed the secretion of proinflammatory cytokines
and chemokines after LPS stimulation. Monocytes from healthy
volunteers secreted high amounts of proinflammatory cytokines
(TNFa, IL6, IL1b) and chemokines (MCP-1, MIP1a, MIP1b)
upon stimulation with LPS (Fig. 7A–B). The chemokine MIG was
not significantly induced by LPS. Monocytes isolated from patients
with advanced cirrhosis did not differ with respect to any of the
cytokines or chemokines analyzed at baseline or after LPS
stimulation (Fig. 7A–B), suggesting that circulating monocytes in
CLD patients preserved overall their normal capacity to secrete
pro- or anti-inflammatory mediators.
Given the marked preferential intrahepatic accumulation of
CD14
+CD16
+ monocytesin liver cirrhosis (Fig. 3),we nextaimed to
definethelikely functionofthissubset inthepathogenesisofchronic
liver inflammation and fibrosis. CD14
+CD16
2 and CD14
+CD16
+
monocytes were isolated by MACS methodology, and cytokine/
chemokine secretion was measured after five days of culture without
additional stimulation. Due to ethical considerations (large blood
volume required for subset isolation) and based on the identical
cytokine secretion of total monocytes upon stimulation (Fig. 7A–B),
monocyte subpopulations were only isolated from healthy volun-
Figure 6. Regulation of chemokine receptors on circulating monocytes in chronic liver disease. (A) Monocytic chemokine receptor gene
expression by real-time PCR after purification of circulating monocytes by CD14 microbeads (MACS). (B) CCR2 expression (MFI, mean fluorescence
intensity) on blood monocyte subsets by FACS. Abbreviations are: HC, healthy control; CLD, chronic liver disease; NC, no cirrhosis; CIR, cirrhosis.
Representative histograms are shown, comparing either CCR2 expression levels between both monocyte subsets as well as between healthy controls
and CLD patients on the two monocyte subpopulations in peripheral blood. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0011049.g006
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+CD16
+ monocytes were the major
producers of TNFa, IL6 (CD14
+CD16
+ vs. CD14
+CD16
2,
p=0.038), IFNc (CD14
+CD16
+ vs. CD14
+CD16
2, p=0.0242),
MIP1a (CD14
+CD16
+ vs. CD14
+CD16
2, p=0.0011) and MIP1b
(Fig. 7C), indicating that they primarily perpetuate inflammatory
processes by releasing proinflammatory cyto- and chemokines. This
conclusion is corroborated by correlations between circulating
CD14
+CD16
+ monocyte counts and proinflammatory serum
cytokine levels (e.g., TNFa, MIP1b) in CLD patients (Table 2).
CD14
+CD16
2 monocytes, on the other hand, were the main
producers of MCP-1 (CD14
+CD16
+ vs. CD14
+CD16
2,
p=0.0068), in line with observations that MCP-1 can stimulate
MCP-1 expression via CCR2 binding in an autocrine manner
[23]. Moreover, CD14
+CD16
2, but not CD14
+CD16
+ monocytes
were capable of producing the antiinflammatory cytokine IL10
(Fig. 7C). Collectively, these data imply that the CD14
+CD16
+
monocytes that accumulate in the fibrotic/cirrhotic liver are
important sources of proinflammatory mediators thereby perpet-
uating the chronic inflammation in the liver.
CD16
+ monocytes directly activate hepatic stellate cells
Monocyte-derived macrophages can activate HSC and hence
are potent inductors of liver fibrosis [18]. In murine models of
hepatic fibrosis, Gr1
+ monocytes (‘classical monocytes’) can
directly activate HSC in a TGFb-dependent manner [6]. We
therefore assessed possible effects of human monocyte subpopu-
lations on HSC by co-culturing either subset with primary HSC
isolated from explanted human livers of three independent donors
(Fig. 8A). The experimental set-up was validated by stimulating
primary HSC by recombinant TGFb, which resulted in significant
up-regulation of col1A mRNA, but not of Acta2; expression of Acta2
could therefore be used as a house-keeping gene for HSC (not
shown). In the co-culture experiments CD14
+CD16
+ monocytes,
but not CD14
+CD16
2 monocytes significantly up-regulated
collagen gene expression in HSC (CD14
+CD16
+ vs.
CD14
+CD16
2, p=0.0243) (Fig. 8B). It could be excluded that
CD14
+CD16
+ monocytes directly differentiated into collagen-
producing fibrocytes in vitro [24], because cultures of monocyte
subsets by itself did not result in detectable collagen mRNA within
five days (not shown). Of note, also the mixed population of
lymphocytes induced HSC activation, highlighting that not only
macrophages, but also NK, NKT and T cell subsets may interact
with HSC during fibrosis development [2]. The activation of HSC
by CD14
+CD16
+ monocytes could be partially blocked by anti-
TGFb antibodies (Fig. 8B). These data indicate that ‘non-classical’
CD14
+CD16
+ monocytes not only provide proinflammatory
cytokines, but also exert direct fibrogenic actions on HSC.
Moreover, co-culture with HSC in turn differentially affected
the expression of chemokine receptors and activation markers of
monocyte subsets. CCR2 and DC-SIGN were strongly induced
upon co-culture with HSC only on CD14
+CD16
+ monocytes
(CCR2 expression at d0 compared to d5, p=0.0147; DC-SIGN
expression at d0 compared to d5, p=0.0004) (Fig. 8C), indicating
that the increase of ccr2 mRNA transcripts in whole liver (Fig. 5A)
might be partially attributed to up-regulated expression by CD16
+
monocyte-derived macrophages. In contrast, HLA-DR was down-
regulated in response to co-culture with HSC in both monocyte
subsets (Fig. 8C). These observations emphasize that monocytes/
Figure 7. Monocytes are functionally active in liver cirrhosis with a differential release of distinct cytokines/chemokines by
monocyte subsets. (A+B) Cytokine/chemokine release of monocyte-derived macrophages (2 days in culture) without stimulation (A) and after
stimulation with 1 mg/ml LPS (B). (C) Cytokine/chemokine release of purified monocyte subsets after 5 days of culture without stimulation. *p,0.05,
**p,0.001.
doi:10.1371/journal.pone.0011049.g007
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the hepatic microenvironment.
Discussion
Accumulating evidence from murine models indicated that
monocyte infiltration into the liver is a major pathogenic factor for
chronic hepatic inflammation and fibrosis [5,6,7,8]. In this study,
we demonstrate that monocytes increase in the circulation as well
as in the liver of patients during progression of chronic liver
disease, and that this is associated with a shift towards the ‘non-
classical’ subset of CD14
+CD16
+ monocytes. These CD14
+CD16
+
cells have an activated phenotype and produce high amounts of
pro-inflammatory cytokines and chemokines upon differentiation.
Given the assumption that CD14
+CD16
+ monocytes would
resemble Gr1
lo cells in mice, our findings reveal a considerable
discrepancy from mouse models, because fibrosis induction and
progression in mice is accompanied by Gr1
hi monocytosis in
peripheral blood and infiltration of Gr1
hi monocytes into the
injured liver [6,7]. One obvious difference between murine models
and the human diseased liver is the strikingly dissimilar time-
course of fibrosis development. Whereas experimental murine
fibrosis is analyzed at three or six weeks after induction, e.g. by
biliary duct ligation or carbon tetrachloride injection, human
fibrosis and cirrhosis usually develops over decades of chronic
injury and inflammation. Human cirrhosis is thereby a more
advanced disease with respect to collagen deposition, tissue
reorganization and myofibroblast activation than even 8-weeks-
murine fibrosis models [25]. In this respect, it is important to point
out that the most prominent enrichment of these non-classical
CD14
+CD16
+ monocytes in peripheral blood and in the liver was
observed in patients with liver cirrhosis, in contrast to the similar
levels observed between healthy volunteers and CLD patients at
early stages of liver fibrosis. This suggests that the proposed pro-
inflammatory and profibrogenic actions of CD14
+CD16
+ mono-
cytes/macrophages are most relevant at advanced fibrosis or
cirrhosis, possibly explaining different observations between
human cirrhosis and experimental mouse models.
The assumption that CD14
+CD16
+ human monocytes are
equivalents of murine Gr1
lo monocytes is primarily based on
conserved gene and protein profiles between these subsets [13],
but not on functional assays. In fact, murine Gr1
hi monocyte-
derived cells in inflammatory conditions and human
CD14
+CD16
+-derived macrophages share important functional
properties, particularly the expression of pro-inflammatory
cytokines such as TNFa or nitric oxide [3,26]. Our study revealed
correlations between CD14
+CD16
+ monocytes and pro-inflam-
matory cytokines/chemokines in patients as well as a preferential
secretion of pro-inflammatory cytokines by this subset, suggesting
that the increase of CD14
+CD16
+ monocytes in patients with liver
cirrhosis as the ‘inflammatory monocyte subset’ thereby mirrors
the increase of Gr1
hi monocytes in murine models.
This raised the question if similar chemokine-pathways are
activated in human liver diseases as in murine experimental
models, given the substantial differences in chemokine receptor
expression between murine Gr1
hi and human CD14
+CD16
+
Figure 8. CD14
+CD16
+, but not CD14
+CD16
2 monocytes directly activate hepatic stellate cells. (A) Primary human HSC were isolated and
co-cultured for 5 days with CD14
+CD16
2, CD14
+CD16
+ monocytes or lymphocytes. No morphological differences were noted on HSC in these
conditions. (B) HSC activation was determined by collagen-1A (col1A) mRNA expression, normalized to the ‘HSC-house keeping gene’ Acta2. (C)
Expression of surface molecules by FACS (MFI, mean fluorescence intensity) on CD14
+CD16
2 (CD14) and CD14
+CD16
+ (CD16) monocytes/
macrophages at day 0, and after 5 days in culture or co-culture with HSC. All results derived from three independent experiments. *p,0.05,
**p,0.001.
doi:10.1371/journal.pone.0011049.g008
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defined an important function of CCR2 and MCP-1/CCL2 for
hepatic fibrosis [5,6,7,8]. In analogy to these findings, upregulated
intrahepatic MCP-1 expression has been described during human
hepatic fibrogenesis, predominantly by HSC, biliary epithelial cells
and macrophages, and directly correlated with the number of
hepatic macrophages in a small group of 15 patients [27]. We
confirmed these observations in our large cohort, as ccl2 and also
ccr2 mRNA transcripts were significantly increased in cirrhotic
livers. However, unlike in mice where MCP-1 is thought to
promote the exit of Gr1
hi monocytes from the bone marrow into
the circulation [6,28], systemic levels of MCP-1 were not
significantly regulated in liver disease patients in comparison to
healthy controls. Moreover, CCR2 expression was moderately
lower in CD14
+CD16
2 monocytes of patients compared to
controls and slightly increased in CD14
+CD16
+ monocytes. This
might possibly indicate distinct local functions of CCR2/MCP-1
interactions in the liver during fibrosis progression, likely not
limited to CCR2
hi-expressing CD14
+CD16
2, but also on
CD14
+CD16
+ monocytes. This hypothesis is corroborated by
the fact that CD14
+CD16
+, but not CD14
+CD16
2 monocytes
strongly upregulate CCR2 expression upon co-culture with HSC.
In-vitro-experiments suggested that MCP-1 may activate the
expression of profibrogenic genes such as TGFb or pro-a1 chain
of type I collagen in monocyte-derived macrophages by an MCP-
1/CCR2-dependent amplification loop [23], indicating that local
intrahepatic MCP-1 may fulfil other functions in addition to
regulating monocyte recruitment in liver cirrhosis.
On the other hand, CCR1- and CCR5-related chemokines
might contribute to monocyte recruitment. It is well established
that HSC express CCL5/RANTES upon activation [29,30]. We
found a clear induction of intrahepatic ccl5 expression, confirming
a smaller prior study including 15 patients [11], alongside elevated
serum CCL3/MIP1a, CCL4/MIP1b and CCL5/RANTES (not
shown) concentrations in patients versus controls. Moreover,
monocytic ccr1 expression, but not ccr5, was increased in patients.
These data demonstrate that monocyte-related chemokine path-
ways targeting CCR2, CCR1 and CCR5 are activated in patients
with liver cirrhosis, likely regulating recruitment (CCR1, CCR5,
CCR2) and local differentiation/activation (CCR2) of monocyte
subsets in patients with chronic liver diseases. However, it is
important to note that CCR1 and CCR5 expression is not
restricted to monocyte/macrophages, but also found on other
immune cells subsets within the, namely T-, NK- and NKT-cell
populations [2,31]. Both CCR1 and CCR5 have also been
described on other non-parenchymal liver cells, including resting
and activated HSC [11,30]. Therefore, elevation of circulating or
intrahepatic CCL3-CCL5 chemokines likely not only influences
monocyte/macrophage recruitment, but also other cell popula-
tions in the diseased liver.
In patients with liver cirrhosis, intrahepatic monocytes/
macrophages are significantly increased [4], and our analysis
revealed that this can be mainly attributed to a selective
accumulation of CD14
+CD16
+ monocytes/macrophages in the
cirrhotic liver. Cells of the monocytic lineage are important
elements of the hepatic inflammation, because these cells can
phagocytize foreign material, present antigen to T cells, and
produce a host of cytokines, including TNFa, IL1 and IL6 [4].
Dissecting the diverse functional capacities of both monocyte
subsets in vitro confirmed that the CD14
+CD16
+ monocyte subset
is the main producer of pro-inflammatory cytokines and
chemokines such as TNFa, IL6, IFNc, MIP1a and MIP1b, while
CD14
+CD16
2 monocytes readily secrete more MCP-1, IL1b and
IL10 [12]. Moreover, in line with experiments co-culturing murine
Gr1
hi monocytes and murine HSC [6], CD14
+CD16
+ monocytes
were also able to directly activate primary human HSC upon co-
culture. These data indicate that non-classical CD14
+CD16
+
monocytes are crucial regulators in the pathogenesis of CLD in
humans by secreting an abundance of cytokines perpetuating
chronic inflammatory processes within the liver and by directly
activating HSC that in turn can secrete multiple chemokines for
monocyte recruitment [18]. Our study furthermore suggests that
the modulation of monocyte-subset recruitment into the liver and
subsequent differentiation in the inflamed hepatic environment
may represent possible novel approaches for interventions
targeting proinflammatory and profibrogenic actions of either
monocyte subset in chronic liver diseases and liver fibrosis.
Methods
Patients and controls
The study protocol was approved by the local ethics committee
(ethics committee of University Hospital Aachen, RWTH
Aachen), and written informed consent was obtained from each
patient. The study was conducted according to the principles
expressed in the Declaration of Helsinki. Inclusion criteria were
either any CLD with a predisposition to liver fibrosis or an already
established liver fibrosis/cirrhosis of any origin. Established
cirrhosis (in contrast to non-cirrhotic CLD) was defined, if imaging
(ultrasound, CT or MRI scan), biopsy or laparoscopy indicated
liver cirrhosis or if cirrhosis-related complications were present.
Patients with established liver cirrhosis were staged according to
Child-Pugh’s criteria [32]. Patients with acute liver failure or acute
hepatitis B or C were not included. Exclusion criteria were
conditions known to directly affect monocyte subset distributions
in humans, specifically ongoing bacterial infections (procalcitonin
concentration above normal value [,0.5 mg/L]), HIV-infection,
systemic steroid medication (prednisolone .7.5 mg/d or equiva-
lent doses) and malignant tumor(s) except hepatocellular or
cholangiocellular carcinoma. Furthermore, patients were excluded
in case of systemic inflammatory response syndrome (SIRS) or
sepsis criteria [33]. The etiologies of liver diseases comprised viral
hepatitis (n=89, 39.4%; HBV n=38, HCV n=51), biliary or
autoimmune disease (n=27, 11.9%; autoimmune hepatitis n=10,
primary biliary cirrhosis n=8, primary sclerosing cholangitis
n=9), alcoholic liver disease (n=65, 28.7%) and other liver
diseases (n=45, 20%, e.g. non-alcoholic steatohepatitis n=7,
hemochromatosis n=4, cryptogenic n=23). Grading and staging
of liver samples (biopsies and explants) were performed according
to Desmet-Scheuer score by one experienced pathologist, who was
fully blinded to any experimental data [34].
As a control group, 181 healthy volunteers were recruited from
the local blood transfusion institute that had normal aminotrans-
ferase activities, no history of liver disease or alcohol abuse and
tested negative for HBV, HCV and HIV infections.
FACS analysis of circulating monocyte subsets and
intrahepatic macrophages
Fresh blood samples were collected by venipuncture in the
morning in EDTA separator tubes from all patients and controls
and promptly applied to PBMC isolation by Ficoll density
gradient, using LSM-1077 (PAA, Pasching, Austria) and standard
protocols [13]. After blocking nonspecific binding, the following
monoclonal antibodies and appropriate isotype controls were used:
CD14, CD16, CD56, HLA-DR, CD3, CD4, CD8, CD56,
CD209/DC-SIGN, CD19 and CD45 (all BD, Heidelberg,
Germany); CCR2, CCR1, CCR5 (R&D Systems, Minneapolis,
MN). Flow cytometric analysis was performed on a FACS-Canto-
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Ashland, OR). In order to exclude that difference in cell isolation
procedures for FACS analysis influences cell counts, absolute
numbers for circulating cells were calculated using the relative
values from FACS and automated WBC counts without the PMN
fraction. Cell surface marker expression was quantified by
determining mean fluorescence intensity minus the respective
isotype control (‘MFI-MFIisotype’). For flow cytometric character-
ization of intrahepatic monocytes, a small piece of fresh liver
biopsy cylinders was minced in PBS and digested with collagenase
type IV (Worthington, Lakewood, NJ) for 30 min at 37uC, and
subjected to staining for FACS [6].
Monocyte separation, RNA isolation and gene expression
analysis
After isolation of PBMC by density gradient, total monocytes
were purified using CD14-microbeads and MACS separation
technique (Miltenyi, Bergisch Gladbach, Germany). FACS
analysis confirmed a purity of .95%. RNA was isolated from
purified blood monocytes by pegGOLD (peqLab, Erlangen,
Germany), and complementary DNA was generated from 1 mg
RNA (Roche, Mannheim, Germany). Quantitative real-time PCR
was performed using SYBR Green Reagent (Invitrogen, Karls-
ruhe, Germany). b-actin values were used to normalize gene
expression. Gene expression was either expressed by fold induction
or arbitrary relative expression [14]. Primer sequences are
available upon request. RNA and gene expression analyses from
liver tissue, cell-culture and co-culture experiments were per-
formed analogously.
Immunofluorescence analysis of intrahepatic monocyte
subsets
After deparaffinization and rehydration, slides were boiled in
citrate buffer, and blocking solution (Vector Labs, Burlingame, CA)
was applied. Rabbit anti-human CD14 antibody (HPA001887;
Sigma), mouse anti-human CD16 (clone 2H7; MBL), or appropri-
ate isotype control antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) were detected by secondary anti-rabbit Cy-3 and anti-
mouse-FITC-antibodies (Jackson ImmunoResearch, West Grove,
PA). Cell nuclei were counterstained with DAPI (Vectashield,
Vector Labs). Slides were then analysed by fluorescence microscopy
(Zeiss, Jena, Germany). Ten bright fields per slide were randomly
chosen for quantitative analysis. The investigator was blinded to the
stage of fibrosis or experimental data.
In vitro stimulation of monocytes
After isolation of PBMC by density gradient, 1610
6 cells/ml
were resolved in 2 ml RPMI (Invitrogen) containing 1% penicillin-
streptomycin (PAA) and 1.5% autologous serum and allowed to
adhere for 35 min in a Petri dish. Non-adherent cells were
discarded. Cells were then cultured for 24 h in 2 ml RPMI (5%
autologous serum, 1% penicillin-streptomycin), followed by
stimulation with 1 mg/ml LPS (Sigma, Hamburg, Germany)
and additional incubation for 24 h.
Cytokine/chemokine expression of human monocyte
subsets ex vivo
PBMC of three different healthy donors were isolated by density
gradient. CD14
+CD16
2 and CD14
+CD16
+ monocytes were
selectively purified by MACS methodology using ‘Monocyte-
isolation-Kit-II’ and ‘CD16
+-monocytes-isolation-kit’, respectively
(Miltenyi). Lymphocytes serving as control cells were isolated from
PBMC after depletion of monocytes with anti-CD14 microbeads.
Purity .90% was confirmed by FACS analysis. Cells were
cultured in RPMI containing 10% BSA and 1% penicillin-
streptomycin (PAA) for 5 days.
Cytokine and chemokine detection
The release of cytokines/chemokines in human serum or in
culture medium supernatant was measured using FlowCytomix
(Bender Medsystems, Austria, Vienna). Measurements were
performed in duplicates at 50 mL sample volume. Serum concen-
trations of MCP-1, MIP1a and MIP1b wereassessed by Cytometric
Bead Assay (BD) according to the manufacturer’s instructions.
Co-culture of monocyte subsets with primary human
stellate cells
Human liver tissue was obtained from patients undergoing
partial liver resection for metastatic liver tumors of colorectal
cancer. Experimental procedures were performed according to
guidelines of the local ethics committee with patient’s informed
consent. Primary human HSC were isolated using EGTA/
collagenase perfusion and pronase incubation as described
previously [35,36]. HSC were separated from other non-
parenchymal liver cells by arabinogalactan gradient ultracentrifu-
gation, yielding HSC that were more than 90% pure and viable.
8610
4 HSC were seeded on uncoated plastic dishes and cultured
in DMEM supplemented with 10% FCS and 100 IU/ml
penicillin-streptomycin. Growth medium was changed daily for
the first 4 days in culture, then every other day thereafter [37].
Monocytes of three different healthy donors were pooled, and
monocyte subsets were isolated as described above. After 7 days in
pre-culture primary human HSC were co-cultured for 5 days with
either CD14
+CD16
2, CD14
+CD16
+ or lymphocytes (each
8610
5 cells/plate). As a positive control, HSC were stimulated
with 5 ng/mL recombinant human TGFb (R&D systems). Col1A
and Acta2 were found to be exclusively expressed in HSC (and not
in PMBC, monocytes/macrophages or lymphocytes), and col1A,
but not Acta2, was induced in HSC by recombinant TGFb.
Therefore, col1A mRNA was normalized to Acta2 expression, in
order to be able to evaluate HSC activation in cultures with mixed
cell populations. In some co-culture assays, 2 ng/ml polyclonal
anti-human TGFb-Ab (sc-146; Santa Cruz) was applied [6].
Statistical analysis
Due to the skewed distribution of most parameters assessed in
patients, data are presented as median, minimum and maximum.
Differences between two groups were assessed by Mann-Whitney-
U-test, multiple comparisons between more than two groups by
Kruskal-Wallis-ANOVA and Mann-Whitney-U-test for post hoc
analysis (SPSS, Chicago, IL). Box plot graphics illustrate
comparisons between subgroups, displaying a statistical summary
of median, quartiles, range and extreme values. The whiskers
extend from the minimum to the maximum value excluding
outside (open circle) and far out (asterisk) values which are shown
as separate points. Correlations between variables were assessed by
Spearman rank correlation test (SPSS).
For the ex vivo and in vitro experiments, bar graphs represent the
mean and the standard error of the mean (SEM). Statistical
comparisons between groups were performed using Mann-
Whitney-U-test (GraphPad Prism). P-values ,0.05 were consid-
ered statistical significant.
Supporting Information
Figure S1 Absolute numbers of circulating monocyte subsets do
not differ between liver disease patients and healthy controls:
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PLoS ONE | www.plosone.org 14 June 2010 | Volume 5 | Issue 6 | e11049Statistical analysis reveals no significant shifts in absolute numbers
of CD14+CD16- and CD14+CD16+ monocytes comparing
healthy controls (n=181) with chronic liver disease patients
(n=226) or non-cirrhotic (n=85) with cirrhotic (n=141) patients.
No significant alterations are observed between the Child’s stages
of cirrhosis either (Child A, n=48; B, n=46; C, n=47). Box plots
are displayed, where the bold black line indicates the median per
group, the box represents 50% of the values, and horizontal lines
show minimum and maximum values of the calculated non-outlier
values; open circles indicate outlier values.
Found at: doi:10.1371/journal.pone.0011049.s001 (0.07 MB
PDF)
Figure S2 Increased HLA-DR expression on CD14+CD16+
monocytes in chronic liver disease: Statistical analysis reveals an
increase in HLA-DR expression (mean fluorescence intensity,
MFI) on CD14+CD16+ monocytes, but not on CD14+CD16-
monocytes comparing healthy controls (n=181) with chronic liver
disease patients (n=226) or non-cirrhotic (n=85) with cirrhotic
(n=141) patients. No significant alterations are observed between
the Child’s stages of cirrhosis (Child A, n=48; B, n=46; C,
n=47). Box plots are displayed, where the bold black line
indicates the median per group, the box represents 50% of the
values, and horizontal lines show minimum and maximum values
of the calculated non-outlier values; open circles indicate outlier
values. Significant differences (U-test) are marked by *p,0.05.
Found at: doi:10.1371/journal.pone.0011049.s002 (0.07 MB
PDF)
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